Navigation Links
AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Date:2/12/2008

an open-label, non-comparative multi-center Phase 2 trial will have as its primary endpoint the partial or complete tumor response rate according to RECIST and/or GCIG guidelines. Secondary endpoints will include time to progression, survival, toxicity as well as adverse effects. The trial will include up to 82 patients (up to 41 with a diagnosis of platinum-resistant ovarian cancer and up to 41 with disseminated endometrial cancer). Patients will be administered an intravenous infusion of 267 mg/m2 of AEZS-108 over a period of 2 hours at a constant rate, every Day 1 of a 21-day (3-week) cycle. The proposed duration of the study treatment is six, three-week cycles. The planned study period is approximately 24 months. Further information on the trial is available at http://www.clinicaltrials.gov.

Prior Phase 1 trial results

On June 3, 2007 positive results of an open, multi-center, sequential group, dose-escalation Phase 1 study in various gynaecological cancers were presented at the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, Illinois. 17 patients with LHRH-receptor positive gynaecological cancers were recruited. AEZS-108 was administered by intravenous infusion over two hours at dosages of 10, 20, 40, 80, 160 and 267 mg/m2. At 160 mg/m2, six patients had a total of 32 cycles and at 267 mg/m2, seven patients had a total of 27 cycles. Most of the patients had been pretreated with various chemotherapies.

The study showed that AEZS-108 was well tolerated by patients with gynaecological tumors. Furthermore, AEZS-108 is the first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to LHRH-receptor expressing tumors. Finally, signs of anti-tumor activity were observed in three out of 13 patients treated with 160 or 267 mg/m2 of AEZS-108, including three patients with complete or partial response.

About AEZS-108

AEZ
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
2. AEterna Zentaris Announces Outcome of Managements Strategic Review
3. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Immtech Reports Fiscal Third Quarter 2008 Results
7. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
10. Bunge Reports Fourth Quarter Net Income of $245 Million
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 ... inner feelings - and those of others. Being able ... senses. Analyze and read people to anticipate their thoughts ... your deepest emotions and feelings to create unique abstract ... of responsive games. Get inside a first-person-shooter as it ...
(Date:5/21/2015)... Bridgewater, NJ (PRWEB) May 21, 2015 ... and a method for diagnostic or therapeutic imaging within ... the apparatus uses an endoscope having a low cost, ... original USPTO filing date was October 18, 2013 and ... The technology enables the physician to customize the ...
(Date:5/21/2015)... 21, 2015 As part of its ... (BDWMC), Sun Health Foundation funded a $3.25 million project ... pharmacy with the most up-to-date features and technology. , ... The pharmacy's 45 staff members will begin moving from ... in the coming days. , The current pharmacy ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... poster presentation at the International Society for Cellular ... chronic Achilles tendinosis currently in a Phase 1/2 ... 29 th from 5:30 PM to 7:00 ...
Breaking Biology Technology:5 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... X-ray studies and fundamental calculations are helping physicists ... some magnetic shape-memory materials, which change shape under ... serve as light weight, compact alternatives to conventional ... require creating materials that exhibit much larger changes ...
... RESEARCH TRIANGLE PARK, N.C. , April 26 Talecris ... 2010 financial results on April 28, 2010 , after the stock ... Eastern Time on April 29, 2010 . , ... Investors and analysts may participate via ...
... NEW YORK , April 26 Reportlinker.com announces that a new market research ... , Future of Red ... http://www.reportlinker.com/p0189383/Future-of-Red-Biotechnology-in-China.html , ... Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and ...
Cached Biology Technology:Talecris Biotherapeutics to Report First Quarter 2010 Financial Results 2Reportlinker Adds Future of Red Biotechnology in China 2Reportlinker Adds Future of Red Biotechnology in China 3Reportlinker Adds Future of Red Biotechnology in China 4Reportlinker Adds Future of Red Biotechnology in China 5Reportlinker Adds Future of Red Biotechnology in China 6Reportlinker Adds Future of Red Biotechnology in China 7Reportlinker Adds Future of Red Biotechnology in China 8Reportlinker Adds Future of Red Biotechnology in China 9Reportlinker Adds Future of Red Biotechnology in China 10Reportlinker Adds Future of Red Biotechnology in China 11Reportlinker Adds Future of Red Biotechnology in China 12Reportlinker Adds Future of Red Biotechnology in China 13Reportlinker Adds Future of Red Biotechnology in China 14Reportlinker Adds Future of Red Biotechnology in China 15Reportlinker Adds Future of Red Biotechnology in China 16Reportlinker Adds Future of Red Biotechnology in China 17Reportlinker Adds Future of Red Biotechnology in China 18
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
(Date:5/14/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has ... in Smart Mobile Devices " report to their ... a watershed year for fingerprint sensors in smartphones and ... gave fingerprint sensors a raison d,etre in the mobile ... a must-have feature in flagship smartphones. The ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... team of scientists and physicians at the Medical College of ... identify and treat an unknown disease. For the one ... at The Medical College of Wisconsin and Children,s Hospital of ... identify a previously-unknown mutation. The team was able not ...
... -- The must-have gift for young female chimpanzees this holiday ... That,s the finding of scientists at Harvard University and ... as dolls, carrying them around until they have offspring of ... frequently. The new work by Sonya M. Kahlenberg and ...
... California, San Diego School of Medicine and Skaggs School of ... an effective backup plan to protect the body from infection ... fails. The study appears in the December 19 online ... innate immune system defends the body against infections caused by ...
Cached Biology News:Scientists and physicians use genetic sequencing to identify and treat unknown disease 2Young female chimpanzees appear to treat sticks as dolls 2Researchers discover human immune system has emergency backup plan 2
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
Green Standard is fluorescein....
...
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
Biology Products: